0.8500
+0.0100
+(1.19%)
At close: 3:25:49 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director | 809.03k | -- | 1955 |
| Ms. Elizabeth Williams C.A., CPA | CFO & Corporate Secretary | 342.12k | -- | 1978 |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer | 864.92k | -- | 1969 |
| Mr. William Wasyl Jarosz | Executive Director | 186.93k | -- | 1956 |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy | 313.54k | -- | 1952 |
| Dr. Michael Cross M.B.A., Ph.D. | Chief Business Officer | 346.07k | -- | 1965 |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer | 120k | -- | 1962 |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration | -- | -- | -- |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor | 44.48k | -- | 1960 |
| Ms. Desiree Chan | Chief of Staff | -- | -- | -- |
Satellos Bioscience Inc.
Royal Bank Plaza
Suite 2800 South Tower 200 Bay Street
Toronto, ON M5J 2J1
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Corporate Governance
Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
MDNA.TO Medicenna Therapeutics Corp.
1.3700
-5.52%
PHRM.CN PharmaTher Holdings Ltd.
0.2150
-6.52%
NGEN.V NervGen Pharma Corp.
3.0900
+3.69%
EPRX Eupraxia Pharmaceuticals Inc.
3.0000
-1.64%
ONCO.CN Onco-Innova
1.2000
0.00%
MDNAF Medicenna Therapeutics Corp.
0.9800
-3.92%
APLI.TO Appili Therapeutics Inc.
0.0350
+16.67%
BLAB.CN Britannia Life Sciences Inc.
0.0850
0.00%
MDMA.CN Pharmala Biotech Holdings Inc.
0.3100
+16.98%
APS.TO Aptose Biosciences Inc.
0.3150
+1.61%